Am J Manag Care.
There were 2 errors in the supplement, "Fracture Prevention in Osteoporosis." First, in Figure 1 on page S192 of the article "Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real-world Setting," by Diana Brixner, PhD, RPh,(2006;12[suppl 7]:S191-S198), the bars representing the VERTNA [Vertebral Efficacy With Risedronate Therapy-North America] study were inadvertently switched with the placebo bars. Second, in the same figure, the acronym VERT-MIN was incorrect; the correct acronym is VERT-MN [Vertebral Efficacy With Risedronate Therapy-Multinational]. The corrected figure appears below.

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis
February 6th 2026Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.
Read More
Building Trust: Public Priorities for Health Care AI Labeling
January 27th 2026A Michigan-based deliberative study found strong public support for patient-informed artificial intelligence (AI) labeling in health care, emphasizing transparency, privacy, equity, and safety to build trust.
Read More
Ambient AI Tool Adoption in US Hospitals and Associated Factors
January 27th 2026Nearly two-thirds of hospitals using Epic have adopted ambient artificial intelligence (AI), with higher uptake among larger, not-for-profit hospitals and those with higher workload and stronger financial performance.
Read More
Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions
January 26th 2026Skilled nursing facilities (SNFs) with a high volume of referred patients with Alzheimer disease and related dementias may work harder to manage care transitions with less availability of resources that enable high-quality handoffs.
Read More